Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Extended delivery of vaccines to the skin improves immune responses.

Joyce JC, Sella HE, Jost H, Mistilis MJ, Esser ES, Pradhan P, Toy R, Collins ML, Rota PA, Roy K, Skountzou I, Compans RW, Oberste MS, Weldon WC, Norman JJ, Prausnitz MR.

J Control Release. 2019 Jun 28;304:135-145. doi: 10.1016/j.jconrel.2019.05.006. Epub 2019 May 6. French.

PMID:
31071375
2.

Hormonal Regulation of Physiology, Innate Immunity and Antibody Response to H1N1 Influenza Virus Infection During Pregnancy.

Littauer EQ, Skountzou I.

Front Immunol. 2018 Oct 29;9:2455. doi: 10.3389/fimmu.2018.02455. eCollection 2018. Review.

3.

Evolution of Two Major Zika Virus Lineages: Implications for Pathology, Immune Response, and Vaccine Development.

Beaver JT, Lelutiu N, Habib R, Skountzou I.

Front Immunol. 2018 Jul 18;9:1640. doi: 10.3389/fimmu.2018.01640. eCollection 2018. Review.

4.

NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?

Krammer F, Fouchier RAM, Eichelberger MC, Webby RJ, Shaw-Saliba K, Wan H, Wilson PC, Compans RW, Skountzou I, Monto AS.

MBio. 2018 Apr 3;9(2). pii: e02332-17. doi: 10.1128/mBio.02332-17. Review.

5.

Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza.

Littauer EQ, Mills LK, Brock N, Esser ES, Romanyuk A, Pulit-Penaloza JA, Vassilieva EV, Beaver JT, Antao O, Krammer F, Compans RW, Prausnitz MR, Skountzou I.

J Control Release. 2018 Apr 28;276:1-16. doi: 10.1016/j.jconrel.2018.02.033. Epub 2018 Feb 26.

6.

H1N1 influenza virus infection results in adverse pregnancy outcomes by disrupting tissue-specific hormonal regulation.

Littauer EQ, Esser ES, Antao OQ, Vassilieva EV, Compans RW, Skountzou I.

PLoS Pathog. 2017 Nov 27;13(11):e1006757. doi: 10.1371/journal.ppat.1006757. eCollection 2017 Nov.

7.

Microneedle patch delivery of influenza vaccine during pregnancy enhances maternal immune responses promoting survival and long-lasting passive immunity to offspring.

Esser ES, Pulit-Penaloza JA, Kalluri H, McAllister D, Vassilieva EV, Littauer EQ, Lelutiu N, Prausnitz MR, Compans RW, Skountzou I.

Sci Rep. 2017 Jul 18;7(1):5705. doi: 10.1038/s41598-017-05940-7.

8.

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.

Rouphael NG, Paine M, Mosley R, Henry S, McAllister DV, Kalluri H, Pewin W, Frew PM, Yu T, Thornburg NJ, Kabbani S, Lai L, Vassilieva EV, Skountzou I, Compans RW, Mulligan MJ, Prausnitz MR; TIV-MNP 2015 Study Group.

Lancet. 2017 Aug 12;390(10095):649-658. doi: 10.1016/S0140-6736(17)30575-5. Epub 2017 Jun 27.

9.

Corrigendum: Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection.

Bohannon C, Powers R, Satyabhama L, Cui A, Tipton C, Michaeli M, Skountzou I, Mittler RS, Kleinstein SH, Mehr R, Lee FE, Sanz I, Jacob J.

Nat Commun. 2016 Aug 16;7:12687. doi: 10.1038/ncomms12687. No abstract available.

10.

Tetanus vaccination with a dissolving microneedle patch confers protective immune responses in pregnancy.

Esser ES, Romanyuk A, Vassilieva EV, Jacob J, Prausnitz MR, Compans RW, Skountzou I.

J Control Release. 2016 Aug 28;236:47-56. doi: 10.1016/j.jconrel.2016.06.026. Epub 2016 Jun 18.

PMID:
27327766
11.

Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection.

Bohannon C, Powers R, Satyabhama L, Cui A, Tipton C, Michaeli M, Skountzou I, Mittler RS, Kleinstein SH, Mehr R, Lee FE, Sanz I, Jacob J.

Nat Commun. 2016 Jun 7;7:11826. doi: 10.1038/ncomms11826. Erratum in: Nat Commun. 2016 Aug 16;7:12687. Lee, Francis Eun-Hyung [Lee, Frances Eun-Hyung].

12.

Long-term stability of influenza vaccine in a dissolving microneedle patch.

Mistilis MJ, Joyce JC, Esser ES, Skountzou I, Compans RW, Bommarius AS, Prausnitz MR.

Drug Deliv Transl Res. 2017 Apr;7(2):195-205. doi: 10.1007/s13346-016-0282-2.

13.

Modulation of influenza vaccine immune responses using an epidermal growth factor receptor kinase inhibitor.

Pulit-Penaloza JA, Sapkota B, Stein Esser E, Compans RW, Pollack BP, Skountzou I.

Sci Rep. 2015 Jul 31;5:12321. doi: 10.1038/srep12321.

14.

Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.

Vassilieva EV, Kalluri H, McAllister D, Taherbhai MT, Esser ES, Pewin WP, Pulit-Penaloza JA, Prausnitz MR, Compans RW, Skountzou I.

Drug Deliv Transl Res. 2015 Aug;5(4):360-71. doi: 10.1007/s13346-015-0228-0.

15.

Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts.

Koutsonanos DG, Esser ES, McMaster SR, Kalluri P, Lee JW, Prausnitz MR, Skountzou I, Denning TL, Kohlmeier JE, Compans RW.

Vaccine. 2015 Sep 8;33(37):4675-82. doi: 10.1016/j.vaccine.2015.01.086. Epub 2015 Mar 3.

16.

Influenza virus-specific neutralizing IgM antibodies persist for a lifetime.

Skountzou I, Satyabhama L, Stavropoulou A, Ashraf Z, Esser ES, Vassilieva E, Koutsonanos D, Compans R, Jacob J.

Clin Vaccine Immunol. 2014 Nov;21(11):1481-9. doi: 10.1128/CVI.00374-14. Epub 2014 Aug 27.

17.

A protective role of murine langerin⁺ cells in immune responses to cutaneous vaccination with microneedle patches.

Pulit-Penaloza JA, Esser ES, Vassilieva EV, Lee JW, Taherbhai MT, Pollack BP, Prausnitz MR, Compans RW, Skountzou I.

Sci Rep. 2014 Aug 18;4:6094. doi: 10.1038/srep06094.

18.

Skin immunization with influenza vaccines.

Skountzou I, Compans RW.

Curr Top Microbiol Immunol. 2015;386:343-69. doi: 10.1007/82_2014_407. Review.

19.

Targeting the skin for microneedle delivery of influenza vaccine.

Koutsonanos DG, Compans RW, Skountzou I.

Adv Exp Med Biol. 2013;785:121-32. doi: 10.1007/978-1-4614-6217-0_13. Review.

20.

ZBTB32 is an early repressor of the CIITA and MHC class II gene expression during B cell differentiation to plasma cells.

Yoon HS, Scharer CD, Majumder P, Davis CW, Butler R, Zinzow-Kramer W, Skountzou I, Koutsonanos DG, Ahmed R, Boss JM.

J Immunol. 2012 Sep 1;189(5):2393-403. doi: 10.4049/jimmunol.1103371. Epub 2012 Jul 30.

21.

Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine.

Weldon WC, Zarnitsyn VG, Esser ES, Taherbhai MT, Koutsonanos DG, Vassilieva EV, Skountzou I, Prausnitz MR, Compans RW.

PLoS One. 2012;7(7):e41501. doi: 10.1371/journal.pone.0041501. Epub 2012 Jul 25.

22.

Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection.

Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, Taherbhai MT, Prausnitz MR, Compans RW, Skountzou I.

Sci Rep. 2012;2:357. doi: 10.1038/srep00357. Epub 2012 Apr 12.

23.

Local response to microneedle-based influenza immunization in the skin.

del Pilar Martin M, Weldon WC, Zarnitsyn VG, Koutsonanos DG, Akbari H, Skountzou I, Jacob J, Prausnitz MR, Compans RW.

MBio. 2012 Mar 6;3(2):e00012-12. doi: 10.1128/mBio.00012-12. Print 2012.

24.

Salmonella flagellin enhances mucosal immunity of avian influenza vaccine in chickens.

Chaung HC, Cheng LT, Hung LH, Tsai PC, Skountzou I, Wang B, Compans RW, Lien YY.

Vet Microbiol. 2012 May 25;157(1-2):69-77. doi: 10.1016/j.vetmic.2011.12.014. Epub 2011 Dec 16.

PMID:
22226542
25.

CIITA promoter I CARD-deficient mice express functional MHC class II genes in myeloid and lymphoid compartments.

Zinzow-Kramer WM, Long AB, Youngblood BA, Rosenthal KM, Butler R, Mohammed AU, Skountzou I, Ahmed R, Evavold BD, Boss JM.

Genes Immun. 2012 Jun;13(4):299-310. doi: 10.1038/gene.2011.86. Epub 2012 Jan 5.

26.

Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination.

Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Jacob J, Prausnitz MR, Compans RW, Skountzou I.

J Infect Dis. 2011 Aug 15;204(4):582-91. doi: 10.1093/infdis/jir094. Epub 2011 Jun 17.

27.

Programming the magnitude and persistence of antibody responses with innate immunity.

Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, García-Sastre A, Compans R, Pulendran B.

Nature. 2011 Feb 24;470(7335):543-7. doi: 10.1038/nature09737.

28.

Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.

Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, Prausnitz MR, Compans RW.

Clin Vaccine Immunol. 2011 Apr;18(4):647-54. doi: 10.1128/CVI.00435-10. Epub 2011 Feb 2.

29.

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.

Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC.

J Exp Med. 2011 Jan 17;208(1):181-93. doi: 10.1084/jem.20101352. Epub 2011 Jan 10. Erratum in: J Exp Med. 2011 Feb 14;208(2):411.

30.

Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.

Weldon WC, Wang BZ, Martin MP, Koutsonanos DG, Skountzou I, Compans RW.

PLoS One. 2010 Sep 1;5(9). pii: e12466. doi: 10.1371/journal.pone.0012466.

31.

Dissolving polymer microneedle patches for influenza vaccination.

Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, Murthy N, Compans RW, Skountzou I, Prausnitz MR.

Nat Med. 2010 Aug;16(8):915-20. doi: 10.1038/nm.2182. Epub 2010 Jul 18.

32.

Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus.

Skountzou I, Koutsonanos DG, Kim JH, Powers R, Satyabhama L, Masseoud F, Weldon WC, Martin Mdel P, Mittler RS, Compans R, Jacob J.

J Immunol. 2010 Aug 1;185(3):1642-9. doi: 10.4049/jimmunol.1000091. Epub 2010 Jun 28.

33.

Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge.

Martin Mdel P, Seth S, Koutsonanos DG, Jacob J, Compans RW, Skountzou I.

PLoS One. 2010 May 28;5(5):e10897. doi: 10.1371/journal.pone.0010897.

34.

Transcutaneous immunization with influenza vaccines.

Skountzou I, Kang SM.

Curr Top Microbiol Immunol. 2009;333:347-68. doi: 10.1007/978-3-540-92165-3_17. Review.

PMID:
19768414
35.

Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine.

Skountzou I, Martin Mdel P, Wang B, Ye L, Koutsonanos D, Weldon W, Jacob J, Compans RW.

Vaccine. 2010 May 28;28(24):4103-12. doi: 10.1016/j.vaccine.2009.07.058. Epub 2009 Aug 3.

36.

Original antigenic sin responses to influenza viruses.

Kim JH, Skountzou I, Compans R, Jacob J.

J Immunol. 2009 Sep 1;183(5):3294-301. doi: 10.4049/jimmunol.0900398. Epub 2009 Jul 31.

37.

Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge.

Zhu Q, Zarnitsyn VG, Ye L, Wen Z, Gao Y, Pan L, Skountzou I, Gill HS, Prausnitz MR, Yang C, Compans RW.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7968-73. doi: 10.1073/pnas.0812652106. Epub 2009 Apr 27.

38.

Transdermal influenza immunization with vaccine-coated microneedle arrays.

Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Sullivan SP, Compans RW, Prausnitz MR, Skountzou I.

PLoS One. 2009;4(3):e4773. doi: 10.1371/journal.pone.0004773. Epub 2009 Mar 10.

39.

Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, Compans RW.

J Virol. 2008 Dec;82(23):11813-23. doi: 10.1128/JVI.01076-08. Epub 2008 Sep 10.

40.

Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.

Quan FS, Sailaja G, Skountzou I, Huang C, Vzorov A, Compans RW, Kang SM.

Vaccine. 2007 May 10;25(19):3841-50. Epub 2007 Feb 15.

41.

Fusogenic variants of a noncytopathic paramyxovirus.

Seth S, Skountzou I, Gernert KM, Compans RW.

J Virol. 2007 Apr;81(8):4286-97. Epub 2007 Feb 7.

42.

Human immunodeficiency virus-like particles activate multiple types of immune cells.

Sailaja G, Skountzou I, Quan FS, Compans RW, Kang SM.

Virology. 2007 Jun 5;362(2):331-41. Epub 2007 Feb 5.

43.

Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles.

Skountzou I, Quan FS, Gangadhara S, Ye L, Vzorov A, Selvaraj P, Jacob J, Compans RW, Kang SM.

J Virol. 2007 Feb;81(3):1083-94. Epub 2006 Nov 15.

44.

Transcutaneous immunization with inactivated influenza virus induces protective immune responses.

Skountzou I, Quan FS, Jacob J, Compans RW, Kang SM.

Vaccine. 2006 Aug 28;24(35-36):6110-9. Epub 2006 May 26.

PMID:
16766095

Supplemental Content

Loading ...
Support Center